Skip to main content
Clinical Trials/EUCTR2006-001389-18-AT
EUCTR2006-001389-18-AT
Active, not recruiting
Phase 1

Comparison of Combined Therapy of Intravitreal Injection of Bevacizumab and Pegaptanib versus Mono-therapy (The MAAM Study) - MAAM-Study

udwig Boltzmann Institute forRetinology and Biomicroscopic Laser Surgery0 sites60 target enrollmentAugust 31, 2006

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
udwig Boltzmann Institute forRetinology and Biomicroscopic Laser Surgery
Enrollment
60
Status
Active, not recruiting
Last Updated
9 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 31, 2006
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
udwig Boltzmann Institute forRetinology and Biomicroscopic Laser Surgery

Eligibility Criteria

Inclusion Criteria

  • age \> 50 years
  • predominantly occult CNV
  • greatest diameter of the lesion \< 5400µm
  • distance acuity \> 0\.1
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Any of the following will exclude a subject from the study:
  • Complicating general disorders inflicting with healing process
  • vision threatening diseases other than CNV
  • Prior treatment for CNV
  • Ophthalmic surgery within 4 weeks

Outcomes

Primary Outcomes

Not specified

Similar Trials